CJC-1295 & GHRP-2 Blend (10mg)

CJC-1295 & GHRP-2 Blend (10mg)

$84.00

Size: 10mg
Contents: CJC-1295 NO DAC (5mg) & GHRP-2 (5mg)
Form: Lyophilized powder
Purity: >99%
SKU: CJC-1295-GHRP-2
FREE Shipping on $200+ orders

Quantity Discount Price
5 – 8 5% $79.80
9 + 10% $75.60
SKU: CJC-1295-GHRP-2 Category:

Certificate Of Analysis

buy cjc-1295 online

Description

 

CJC-1295 & GHRP-2 Peptide Blend 

Overview
The CJC-1295 & GHRP-2 peptide blend represents a combination of two peptides that may act synergistically to stimulate endogenous growth hormone (GH) secretion. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), while GHRP-2 is a synthetic hexapeptide analog of ghrelin, classified as a growth hormone secretagogue (GHS). By interacting with distinct receptors—CJC-1295 at GHRH receptors and GHRP-2 at GHS-R1a receptors—this blend is hypothesized to enhance GH pulsatility and amplify downstream anabolic signaling through IGF-1.

Peptide Composition and Chemistry

Peptide Amino Acids Molecular Formula Molecular Weight Other Names
CJC-1295 29 (tetrasubstituted GRF 1-29) C152H252N44O42 3367.9 g/mol GRF 1-29 albumin conjugate, GHRH Derivative
GHRP-2 6 (hexapeptide) C45H55N9O6 817.9 g/mol Pralmorelin, GPA-748

Structural Features of CJC-1295:

  • Derived from GHRH 1-29, with four amino acid substitutions to increase stability and bioactivity.

  • May include a DAC (Drug Affinity Complex) component, which binds plasma proteins to prolong half-life and maintain receptor affinity.

  • Enhances GH secretion over extended periods compared to endogenous GHRH.

Structural Features of GHRP-2:

  • Hexapeptide ghrelin analog that binds GHS-R1a receptors in the hypothalamus and pituitary.

  • Stimulates GH release while influencing appetite and energy balance via hypothalamic neuropeptides (NPY, AgRP) and mesolimbic pathways.

  • May attenuate catabolic effects in muscle through GH-dependent pathways.

Mechanism of Action

  1. CJC-1295

    • Binds to GHRH receptors on anterior pituitary somatotrophs.

    • Activates G-protein coupled pathways, leading to cAMP-mediated signaling, transcription factor phosphorylation, and increased GH gene expression.

    • Prolonged stimulation contributes to sustained GH and IGF-1 elevation.

  2. GHRP-2

    • Binds to GHS-R1a receptors, antagonizing somatostatin and triggering rapid GH release.

    • Influences hypothalamic appetite-regulating peptides (NPY, AgRP) and may impact energy homeostasis.

  3. Synergistic Effect

    • CJC-1295 maintains GH secretion over time, while GHRP-2 provides an initial GH surge.

    • Synergism can result in pulsatile GH release, preventing supraphysiologic peaks while maximizing anabolic and regenerative effects.

    • Studies suggest combined administration can increase pulsatile GH secretion by 54-fold compared to controls.

Pharmacokinetics

Peptide Half-Life Duration of Action
CJC-1295 (No DAC) ~30 minutes Moderate GH elevation; effect 1–3 days
CJC-1295 (DAC) ~6–8 days Sustained GH elevation; prolonged IGF-1 effect
GHRP-2 ~15–60 minutes Rapid GH stimulation; short-acting

Physiological Effects

  • Muscle & Fat Metabolism: GH-induced lipolysis, fatty acid utilization, and protein synthesis. GHRP-2 may stimulate appetite, potentially balancing energy intake with anabolic growth.

  • IGF-1 Activation: GH released from pituitary binds liver receptors, activating JAK-STAT pathways, leading to IGF-1 transcription and systemic anabolic effects.

  • Lean Muscle Gain: Elevated GH and IGF-1 support muscle hypertrophy, tissue repair, and anti-catabolic processes.

  • Energy Balance: GHRP-2 may increase hunger while promoting GH-driven fat metabolism, influencing overall energy homeostasis.

Research Findings

  • Clinical studies suggest CJC-1295 may increase mean plasma GH by 2- to 10-fold and IGF-1 by 1.5- to 3-fold for extended periods.

  • GHRP-2 accelerates time to peak GH secretion by 43% and can independently induce a 47-fold increase in pulsatile GH.

  • Synergistic administration with CJC-1295 results in higher GH pulsatility and prolonged IGF-1 elevation, enhancing potential anabolic outcomes.

  • Preclinical studies indicate potential for lean mass gain, anti-catabolic muscle effects, and tissue repair.

Applications

  • Laboratory research on GH secretion, IGF-1 signaling, and anabolic pathways.

  • Studies on muscle hypertrophy, tissue regeneration, and metabolism.

  • Research into energy homeostasis, appetite regulation, and GH pulsatility modulation.

Important Note: This peptide blend is intended for research and laboratory purposes only and is not approved for therapeutic use in humans. Proper laboratory protocols must be followed.

References

  1. Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792–4797. doi:10.1210/jc.2006-1702

  2. Yamamoto D, et al. Life Sci. 2008;82(9-10):460–466. doi:10.1016/j.lfs.2007.11.019

  3. PubChem CID 91976842, CJC1295 Without DAC

  4. PubChem CID 161340, GHRP-2 (Pralmorelin)

  5. Synergistic GH Secretion Research Studies

Related Products